AGN Allergan Dashboard

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands andbest-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

Company profile

Ticker

AGN

Exchange

NYSE

Website

www.allergan.com

CEO

Brenton L. Saunders

Incorporated

Ireland

Location

Ireland

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals: Generic

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Viatris • Bristol-Myers Squibb • Warner Chilcott • Abbvie ...

Former names

Actavis Ltd, Actavis plc

SEC CIK

0001578845

Corporate docs

Articles of Incorporation & Bylaws

AGN stock data

S&P 500

1M 1Y 2Y 5Y

Press releases

Pro users get this 30m faster

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc and Encourages Investors with Losses to Contact the Firm

13 Apr 21

Los Angeles, California--(Newsfile Corp. - April 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allergan plc

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc and Encourages Investors with Losses to Contact the Firm

2 Apr 21

Los Angeles, California--(Newsfile Corp. - April 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allergan plc

Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography

24 Feb 21

Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is projected

Calendar

7 May 20

18 May 21

31 Dec 21

Recent insider trades

AGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
8 May 20	Coughlin Christopher J	Ordinary Shares, par value $0.0001	Sale back to company	Dispose D	No	No	0	16,532	0	0
8 May 20	Coughlin Christopher J	Ordinary Shares, par value $0.0001	Sale back to company	Dispose D	Yes	No	0	9,538	0	16,542
8 May 20	Coughlin Christopher J	Ordinary Shares, par value $0.0001	Sale back to company	Dispose D	Yes	No	0	471	0	26,080
8 May 20	Coughlin Christopher J	Stock Options Ordinary Shares	Sale back to company	Dispose D	No	No	70.79	9,446	668.68K	0
8 May 20	Coughlin Christopher J	Stock Options Ordinary Shares	Sale back to company	Dispose D	No	No	73.14	3,691	269.96K	0
8 May 20	Coughlin Christopher J	Stock Options Ordinary Shares	Sale back to company	Dispose D	No	No	90.22	2,790	251.71K	0
8 May 20	William Meury	RSU	Sale back to company	Dispose D	No	No	0	25,201	0	0
8 May 20	William Meury	Ordinary Shares, par value $0.0001	Sale back to company	Dispose D	No	No	0	7,434	0	0
8 May 20	William Meury	Performance Stock Units Ordinary Shares	Sale back to company	Dispose D	No	No	0	26,506	0	0
8 May 20	William Meury	Stock Options Ordinary Shares	Sale back to company	Dispose D	No	No	196.16	12,304	2.41M	0

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AGN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	4	-50.0%
Opened positions	2	2	–
Closed positions	4	6	-33.3%
Increased positions	0	0
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	3.06M	21.89M	-86.0%
Total shares	17.31K	222.32K	-92.2%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
TMP Tompkins Financial	17.04K	$3.02M	NEW
Founders Capital Management	276	$46K	NEW
IFP Advisors	0	$0

Largest transactions	Shares	Bought/sold	Change
Ashburton	0	-195.5K	EXIT
New Mexico Educational Retirement Board	0	-23.73K	EXIT
TMP Tompkins Financial	17.04K	+17.04K	NEW
Belpointe Asset Management	0	-2.34K	EXIT
JDC-JSC	0	-750	EXIT
Founders Capital Management	276	+276	NEW
IFP Advisors	0	0

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • TherapeuticsMD • AMGEN • Hologic • Veru • Vivus • Royalty Pharma • Palatin • Integra Lifesciences • IRIDEX

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: alpha, API, argument, Asia, AstraZeneca, autoimmune, behavior, biodegradable, broadest, built, buyer, Cadila, certainty, chain, composition, confirm, confirming, contamination, continent, Coolsculpting, CoolTone, Cream, cystic, declare, deliver, detailing, discontinuation, discontinued, distancing, Durysta, electronic, enrolling, environment, enzyme, Esthetique, evolve, exocrine, experienced, Gedeon, genericization, glaucoma, globe, half, home, hypertension, inability, indirectly, inhibitor, innovation, insufficiency, intracameral, intraocular, IOP, Ireland, Lab, Lazeo, LIBOR, lifetime, local, logistical, losing, medial, minute, mitigate, Nestle, OAG, ocular, OHT, outbreak, Pacific, pancreatic, pandemic, patient, pressure, rebate, recession, recovery, relationship, remotely, reply, Richter, satisfaction, Science, shelter, spent, spread, strain, susceptible, suspended, temporarily, Ubrelvy, unemployment, Viokace, Vital

Removed: absence, acceleration, acid, add, adjunctive, advancement, affirming, Akorn, Akron, Apotex, appellate, applied, Argentum, asserting, authorize, automatically, back, binding, BioMed, Biomedical, Body, bound, buy, calculate, calculated, capitalized, capitalizing, Center, centralized, certiorari, chosen, clarify, cloud, collateralization, collateralized, commonly, computing, concurrently, Contouring, contractually, conversion, correct, corrected, Corrupt, cumulative, delaying, Delzicol, denial, denying, Depressive, dermatology, determining, Deva, disgorgement, Disorder, dozen, Easement, enablement, enacted, enforceable, Envy, equaled, equipment, equitable, error, established, estate, Europe, exemption, exercised, expedient, explicitly, Famy, fiscal, fleet, fourth, Framework, gamma, GILTI, ground, Harbor, HD, higher, hosted, immunity, implementation, implicit, implicitly, improper, incorrectly, India, Influenced, InnoPharma, institute, instrument, intent, invalidity, inventorship, issuing, joinder, LA, land, lease, leasing, Legacy, legally, lessee, lessor, Lidoderm, LifeCell, limit, Low, mandatorily, mandatory, MDD, modified, modify, noncancelable, notification, offsetting, older, opening, option, orphan, ownership, package, pattern, Pennsylvania, pension, permission, pertaining, Pharmacal, pivotal, plant, Plastic, postretirement, practical, preferred, prepaid, preventing, privately, pronouncement, prospectively, purpose, qualify, Racketeer, rapastinel, rating, reaching, real, receptor, reclassification, reclassify, recognition, redeemed, refinancing, released, remove, renew, renewal, rental, Replacement, represented, requiring, residual, restitution, resurfacing, retinoic, retired, retrospective, retrospectively, revaluation, reversing, RORyt, ROU, SA, scaling, shortened, skin, Slayback, software, sovereign, standalone, statutory, stranded, substantive, substitute, Subtopic, suit, supplier, Surgery, suspension, Targeted, Taxed, TCJA, terminate, Therapy, threshold, topline, treble, tribal, TWi, Ubrogepant, unrelated, updated, USD, vendor, VI, Vitae, withdraw, withdrew, writ

From filing 10-Q 2020 Q1